Print
Email
Print Edition StoriesTuesday, December 1, 2009
EpiVax, Roche collaborate on immune response tech
By Mass High Tech staff
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: Technology to keep seniors healthy
EpiVax Inc., a Providence, R.I.-based vaccine-focused biotechnology firm, has signed a collaborative agreement with Roche to evaluate the former’s technology intended to improve immune response to certain drugs. As part of the agreement, EpiVax’s Tregitope technology may be used nonexclusively by Roche in its line of protein therapeutic drugs.
Tregitope technology relies on the body’s natural regulatory T cells to help ease the response of antigens or protein immunogens. A news release from EpiVax indicates the company’s belief that the Tregitope technology could help treat auto-immune disorders, as well as applications for allergies, transplants, deimmunization, animal health and chronic infectious disease.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
